Compare Biogen Inc (BIIB) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Orion Office REIT Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Orion Office REIT Inc trades at $2.78 (market cap $158.01M). The key difference: Biogen Inc is far larger — about 190.7× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.89% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | ONL | |
|---|---|---|
Market Cap | $30.13B | $158.01M |
Sector | Health | Real Estate |
52-Week High | $216.63 | $3.04 |
52-Week Low | $128.93 | $1.93 |
Enterprise Value | $37.20B | $574.95M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
ONL trades at $2.83, up 2.91% with a bullish technical signal and strong moving average support. The company reported mixed Q2 2026 results with an EPS beat but continues to face fundamental challenges including declining revenue from $208M in 2022 to $148M in 2025 and negative net margins. Recent news highlights strategic review progress and portfolio repositioning efforts.
The outlook remains cautious despite technical strength. While the stock shows bullish momentum and pays consistent dividends, persistent revenue declines, negative profitability metrics, and high debt levels pose significant risks. Analyst sentiment is evenly split between Buy and Hold recommendations, reflecting uncertainty about the company's turnaround strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
